HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L S Young Selected Research

tretazicar

1/2008Combining gene and immunotherapy for prostate cancer.
8/2005Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
7/2004Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
9/2003Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
2/2001Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
6/2000Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
5/2000Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


L S Young Research Topics

Disease

19Neoplasms (Cancer)
01/2015 - 02/2000
7Breast Neoplasms (Breast Cancer)
07/2015 - 10/2004
6Carcinoma (Carcinomatosis)
11/2009 - 06/2000
5Colorectal Neoplasms (Colorectal Cancer)
01/2008 - 02/2000
4Hodgkin Disease (Hodgkin's Disease)
04/2004 - 06/2001
3Carcinogenesis
05/2014 - 05/2000
3Melanoma (Melanoma, Malignant)
06/2011 - 12/2000
3Hepatocellular Carcinoma (Hepatoma)
11/2006 - 05/2000
3Necrosis
04/2002 - 06/2000
2Disease Progression
06/2011 - 10/2004
2Infections
10/2004 - 06/2000
2Transitional Cell Carcinoma
05/2003 - 05/2000
2Urinary Bladder Neoplasms (Bladder Cancer)
05/2003 - 05/2000
2Epstein-Barr Virus Infections
11/2001 - 10/2000
2Body Weight (Weight, Body)
08/2001 - 10/2000
2Nasopharyngeal Carcinoma
06/2001 - 04/2001
1Residual Neoplasm
01/2015
1Nevus (Nevi)
06/2011
1Prostatic Neoplasms (Prostate Cancer)
01/2008
1Lymphatic Metastasis
11/2006
1Pituitary Neoplasms (Pituitary Adenoma)
12/2004
1Lymphadenitis (Adenitis)
10/2004
1Lung Diseases (Lung Disease)
10/2004
1Foreign Bodies (Foreign Body)
10/2004
1Paraneoplastic Cerebellar Degeneration
05/2004
1Ovarian Epithelial Carcinoma
04/2002
1Colonic Neoplasms (Colon Cancer)
10/2001
1Lymphoma (Lymphomas)
09/2001
1Ureteral Obstruction
03/2001
1Acquired Immunodeficiency Syndrome (AIDS)
10/2000

Drug/Important Bio-Agent (IBA)

14Proteins (Proteins, Gene)FDA Link
07/2015 - 05/2000
10ProdrugsIBA
01/2008 - 02/2000
8EnzymesIBA
01/2008 - 02/2000
7tretazicarIBA
01/2008 - 05/2000
6NitroreductasesIBA
01/2008 - 05/2000
4Transcription Factors (Transcription Factor)IBA
01/2015 - 04/2001
3Membrane Proteins (Integral Membrane Proteins)IBA
11/2009 - 09/2001
3CytokinesIBA
04/2002 - 08/2000
2Steroid Receptors (Steroid Receptor)IBA
07/2015 - 01/2015
2Growth Factor ReceptorsIBA
01/2015 - 10/2004
2Biomarkers (Surrogate Marker)IBA
05/2014 - 06/2011
2Epidermal Growth Factor (EGF)IBA
05/2013 - 05/2008
2DNA (Deoxyribonucleic Acid)IBA
06/2011 - 11/2006
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2008 - 11/2006
2AntigensIBA
11/2006 - 12/2000
2Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
04/2002 - 09/2001
2NF-kappa B (NF-kB)IBA
04/2002 - 04/2001
2Caspase 8 (Caspase-8)IBA
03/2002 - 08/2000
2LigandsIBA
03/2002 - 08/2000
2Pharmaceutical PreparationsIBA
03/2002 - 02/2001
2TNF Receptor-Associated Factor 1IBA
09/2001 - 06/2001
2Type I Tumor Necrosis Factor ReceptorsIBA
06/2001 - 08/2000
1TamoxifenFDA LinkGeneric
07/2015
1HMGB2 ProteinIBA
07/2015
1Aromatase InhibitorsIBA
07/2015
1SurvivinIBA
01/2015
1Tyrosine Kinase InhibitorsIBA
01/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2015
1Trastuzumab (Herceptin)FDA Link
01/2015
1Progesterone Receptors (Progesterone Receptor)IBA
05/2013
1Phenobarbital (Luminal)FDA Link
05/2013
1Estrogen ReceptorsIBA
05/2013
1Junctional Adhesion Molecule AIBA
05/2013
1Dasatinib (BMS 354825)FDA Link
06/2011
1Phosphotransferases (Kinase)IBA
06/2011
1MART-1 AntigenIBA
06/2011
1VaccinesIBA
06/2011
1SteroidsIBA
05/2008
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2008
1Plasminogen Activator Inhibitor 1IBA
06/2007
1SecurinIBA
12/2004
1Nuclear Receptor Coactivator 1IBA
11/2004
1Protein Isoforms (Isoforms)IBA
11/2004
1Indicators and Reagents (Reagents)IBA
10/2004
1Antineoplastic Agents (Antineoplastics)IBA
07/2004
1anti-Yo autoantibodiesIBA
05/2004
1EpitopesIBA
05/2004
1Interferon-gamma (Interferon, gamma)IBA
05/2004
1CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)IBA
04/2004
1Death Domain ReceptorsIBA
03/2002
1beta CateninIBA
10/2001
1beta-Galactosidase (Lactaid)IBA
10/2001
1TCF Transcription FactorsIBA
10/2001
1telithromycin (Ketek)FDA Link
08/2001
1Type II Tumor Necrosis Factor ReceptorsIBA
06/2001
1ChemokinesIBA
06/2001
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
04/2001
1Nitric Oxide (Nitrogen Monoxide)FDA Link
03/2001
1AntibodiesIBA
02/2001
1Peptides (Polypeptides)IBA
12/2000
1Ethambutol (Myambutol)FDA LinkGeneric
10/2000
1Clarithromycin (Biaxin)FDA LinkGeneric
10/2000
1benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA
08/2000

Therapy/Procedure

11Therapeutics
07/2015 - 02/2000
4Immunotherapy
01/2008 - 09/2000
4Ligation
04/2002 - 08/2000
1Catheters
10/2004
1Chemoradiotherapy
05/2003
1Drug Therapy (Chemotherapy)
02/2001
1Oncolytic Virotherapy
01/2001